Aligos Therapeutics, Inc. (ALGS) Stock Forecast
Data as of Aug 8, 2026Healthcare · Current price $5.61 (+1.81%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
ALGS vs Sector & Market
| Metric | ALGS | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 1 | 8 | 18 |
| Target Upside | +256.5% | +16286.1% | +14.7% |
| P/E Ratio | -2.70 | 3.59 | 36.06 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $1M | $1M | $1M | 3 |
| 2027-12-31 | $2M | $2M | $2M | 4 |
| 2028-12-31 | $69M | $69M | $69M | 3 |
| 2029-12-31 | $192M | $192M | $192M | 2 |
| 2030-12-31 | $335M | $335M | $335M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-6.95 | $-6.67 | $-6.39 | 3 |
| 2027-12-31 | $-6.45 | $-4.95 | $-3.45 | 3 |
| 2028-12-31 | $-5.66 | $-1.68 | $9.08 | 4 |
| 2029-12-31 | $2.86 | $2.86 | $2.86 | 2 |
| 2030-12-31 | $5.23 | $5.23 | $5.23 | 2 |
Frequently Asked Questions
What is the analyst consensus for ALGS?
The consensus among 1 analysts covering Aligos Therapeutics, Inc. (ALGS) is Buy with an average price target of $20.00.
What is the highest price target for ALGS?
The highest analyst price target for ALGS is $20.00.
What is the lowest price target for ALGS?
The lowest analyst price target for ALGS is $20.00.
How many analysts cover ALGS?
1 analysts have issued ratings for Aligos Therapeutics, Inc. in the past 12 months.
Is ALGS a buy or sell right now?
Based on 1 analyst ratings, ALGS has a consensus rating of Buy (2.00/5) with a +256.5% upside to the consensus target of $20.00.
What are the earnings estimates for ALGS?
Analysts estimate ALGS will report EPS of $-6.67 for the period ending 2026-12-31, with revenue estimated at $1M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.